The World Health Organization has issued new guidance on the recommended COVID-19 vaccine antigen composition to better align boosters with the current evolution of SARS-CoV-2. Following a decision-making meeting in May 2026, the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) advised manufacturers to utilize the monovalent LP.8.1 antigen.
The update comes as part of a twice-yearly review process designed to enhance vaccine-induced immune responses against circulating variants. While the virus continues to cause severe disease and death globally, the WHO noted that the overall impact on health systems has diminished significantly since the early years of the pandemic, thanks to improved clinical management and widespread population immunity from both prior infections and vaccinations.
For the general public, the most critical takeaway is that the pursuit of a perfectly matched vaccine should not lead to complacency. Health authorities emphasize that vaccination remains a primary public health countermeasure and should not be delayed while waiting for updated formulations to become available in specific regions.
The Shift to LP.8.1 and Alternative Approaches
The recommendation for monovalent LP.8.1 is based on its ability to induce broadly cross-reactive immune responses in populations that already have high levels of prior exposure to the virus. This antigen is intended to provide a more robust shield against the dominant lineages currently circulating.
However, the WHO has left room for flexibility. The TAG-CO-VAC stated that other antigens, such as XFG or NB.1.8.1, may also be used if they demonstrate broad and robust neutralizing antibody responses or proven efficacy against the variants currently in circulation. This approach allows manufacturers to adapt based on the specific platforms they use, whether mRNA or recombinant protein-based vaccines.
The transition to LP.8.1 is already underway. Several manufacturers updated their formulations following a previous recommendation in December 2025, and many of these vaccines have already received regulatory approval and entered national vaccination programs.
Mapping the Viral Landscape in 2026
The decision to prioritize LP.8.1 is rooted in a complex map of viral evolution. Currently, the world is seeing a divergence in which variants dominate different regions. While the XFG variant has been the predominant sequence globally, its proportion has begun to decline. Meanwhile, in the WHO Western Pacific Region, the NB.1.8.1 variant has taken the lead.
Of particular interest to researchers is the rise of the BA.3.2 variant. Unlike the JN.1-descendant variants (which include LP.8.1, XFG, and NB.1.8.1), BA.3.2 is antigenically distinct. This means it looks different to the immune system, making it harder for vaccines designed for the JN.1 lineage to neutralize it effectively.
| Variant Lineage | Current Status | Antigenic Relationship |
|---|---|---|
| LP.8.1 / XFG / NB.1.8.1 | Predominant / Descendants of JN.1 | Closely related; high cross-neutralization |
| BA.3.2 | Increasing globally | Distinct; limited cross-reactivity with JN.1 |
Data suggests that BA.3.2 may have lower “fitness” than JN.1-descendants, which explains why it hasn’t completely displaced them. Interestingly, BA.3.2 appears more frequently in sequences from young children than adults. Scientists suggest this may be due to a lack of cross-reactive immunity in children who were not exposed to earlier versions of the virus.
Evaluating Vaccine Effectiveness and Immunity
To reach this recommendation, the TAG-CO-VAC reviewed a vast array of evidence, including animal antisera tests, human immunogenicity data, and relative vaccine effectiveness (rVE) estimates. The goal of rVE is to measure the incremental protection a new vaccine provides over and above the immunity a person already has from previous shots or infections.
The evidence showed that individuals immunized with LP.8.1 saw significant increases in neutralizing activity against JN.1 and its descendants, including the XFG and NB.1.8.1 variants. While the response to BA.3.2 was lower, the LP.8.1 antigen still provided a broader overall immune response compared to candidate vaccines targeting BA.3.2 specifically, which showed lower overall immunogenicity.
Despite these findings, the WHO acknowledged significant gaps in the available data. You’ll see persistent delays in the reporting of cases, hospitalizations, and deaths from various Member States. This lack of consistent genomic surveillance makes it difficult for experts to predict the exact timing and impact of future mutations with total certainty.
Who Should Prioritize Vaccination?
As the pandemic enters a phase of routine management, the focus has shifted toward protecting the most vulnerable. Following recommendations from the Strategic Advisory Group of Experts on Immunization (SAGE) in March 2026, the WHO advises that Member States prioritize routine vaccination for groups at the highest risk of severe disease.
These high-risk groups typically include the elderly, individuals with significant comorbidities, and the immunocompromised. For these populations, the added protection offered by an updated monovalent vaccine is critical in preventing hospitalization and death, regardless of whether the vaccine is a perfect antigenic match for every circulating sub-variant.
The World Health Organization continues to encourage the development of next-generation vaccines that can not only protect against severe disease but also reduce the overall transmission of SARS-CoV-2.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare provider for personalized vaccination guidance based on your health history.
The TAG-CO-VAC is scheduled to reconvene in approximately six months to evaluate the continued evolution of the virus and determine if further updates to the vaccine antigen composition are necessary. Official updates will be published on the WHO website following the next review.
Do you have questions about the latest vaccine updates? Share this article or leave a comment below to join the conversation.
